Navigation Links
AxoGen, Inc. Receives Grant in Partnership with Vanderbilt University from U.S. Department of Defense
Date:5/23/2013

Alachua, FL (PRWEB) May 23, 2013

AxoGen, Inc. (OTCBB: AXGN), a leading regenerative medicine company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, today announced that the Company and Vanderbilt University have been awarded a shared $1.1 million grant, for which AxoGen’s portion is approximately 35%, from the Congressional Directed Medical Research Programs administrated by the U.S. Department of Defense (DoD) to support the development and expansion of nerve repair technologies.

Erick DeVinney, Director Clinical and Translational Sciences at AxoGen, said, “We are excited that the Department of Defense has recognized and reinforced the clinical value of AxoGen’s peripheral nerve repair platforms in the treatment of traumatic injuries. This grant supports our goal of providing new, life improving solutions for peripheral nerve injuries for wounded warriors and for civilian patients.”

The grant was awarded by the DoD’s Peer Reviewed Orthopaedic Research Program (PRORP) to support a development program jointly led by Wesley Thayer, MD, PhD, Assistant Professor at Vanderbilt University’s Department of Plastic Surgery and Curt Deister, PhD, of AxoGen.

Dr. Thayer added, “Grant funding and collaboration with industry partners helps ensure the translation of innovative technologies from the research lab to clinical use in patients. We are pleased to partner with AxoGen to make advances in the field of peripheral nerve repair.”

AxoGen’s peripheral nerve regeneration technologies are also involved in additional PRORP grant-funded projects in collaboration with the regenerative medicine and orthopedic research divisions of two other prestigious academic institutions. For more information on AxoGen and its technology, please visit http://www.axogeninc.com.

About AxoGen, Inc.
AxoGen (AXGN) is a regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. The Company’s innovative approach to regenerative medicine has resulted in first-in-class products that will define their product categories. AxoGen’s products offer a full suite of surgical nerve reconstruction solutions including Avance® Nerve Graft, the only commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa ECM coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce coaptation sites while preventing soft tissue attachments. For more information, visit our website at http://www.axogeninc.com.

AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen’s principal executive office and operations are located in Alachua, FL.

Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “continue”, “may”, “should”, “will” variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product commercialization and marketing efforts for its portfolio of peripheral nerve repair products, Avance® Nerve Graft, AxoGuard® Nerve Connector and AxoGuard® Nerve Protector, product development, and the intent to list on a national securities exchange. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen’s business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen’s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10763755.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. AxoGen, Inc. Files Form S-1 Registration Statement
2. AxoGen, Inc. Announces CE Mark Approval for AxoGuard® Nerve Protector and AxoGuard® Nerve Connector
3. AxoGen, Inc. Announces Release Date of First Quarter 2013 Results and Conference Call
4. AxoGen, Inc. to Highlight Products at the American Academy of Orthopedic Surgeons 2013 Meeting
5. AxoGen, Inc. Appoints Shawn McCarrey as Vice President of Sales
6. AxoGen, Inc. Announces Presentation of Avance® Nerve Graft Data at American Society for Peripheral Nerve & American Society for Reconstructive Microsurgery 2013 Meetings
7. AxoGen, Inc. Announces Presentation of Avance® Nerve Graft Data at American Association for Hand Surgery 2013 Annual Meeting
8. AxoGen, Inc. to sponsor Educational Symposium and Panel Discussion at 2013 Annual Meetings of American Association for Hand Surgery, American Society for Peripheral Nerve, and American Society for Reconstructive Microsurgery
9. Fresh Healthy Vending Receives Recent National and Local Media Focus
10. Pamela Isom, President and CEO of ICE Safety Solutions Inc. Receives 2013 Women of Influence Recognition and Award
11. Heart valve repair innovator receives Cedars-Sinai Heart Institutes Corday Prize in Heart Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology: